Home Data Calendar Blog

AKBA

Tables

2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30

Common Stock Value 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Weighted Average Number Of Diluted Shares Outstanding 186.82 184.77 NA 183.88 190.38 179.60 NA 173.78 161.33 153.82 NA 143.31 NA NA NA NA NA NA NA NA NA NA 49.72 46.94 40.82

Weighted Average Number Of Shares Outstanding Basic 186.82 184.77 NA 183.88 183.60 179.60 NA 173.78 161.33 153.82 NA 143.31 NA NA NA NA NA NA NA NA NA NA 47.35 46.94 40.82

Earnings Per Share Basic -0.06 -0.14 -0.04 -0.28 0.16 -0.35 -0.40 -0.34 -0.51 -0.45 -0.59 -0.42 -1.28 NA NA NA NA NA NA NA NA NA 0.26 -0.49 -0.53

Earnings Per Share Diluted -0.06 -0.14 -0.04 -0.28 0.15 -0.35 -0.40 -0.34 -0.51 -0.45 -0.59 -0.42 -1.28 NA NA NA NA NA NA NA NA NA 0.25 -0.49 -0.53

2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30

Revenue From Contract With Customer Excluding Assessed Tax 56.38 40.13 55.18 48.96 126.76 61.70 59.60 48.76 52.91 52.30 56.70 59.99 90.14 88.48 69.56 91.98 100.80 72.67 59.85 53.17 48.79 45.93 90.56 41.28 28.52

Cost Of Revenue 17.28 19.48 -3.10 37.95 18.60 31.34 50.35 15.94 52.49 34.61 63.23 30.34 174.62 27.71 38.15 38.26 37.67 31.26 7.77 NA NA NA NA NA NA

Cost Of Goods And Services Sold 17.28 19.48 -3.10 37.95 18.60 31.34 50.35 15.94 52.49 34.61 63.23 30.34 174.62 18.61 38.15 29.16 28.57 22.16 7.77 NA NA NA NA NA NA

Cost Of Goods And Service Excluding Depreciation Depletion And Amortization 8.27 10.47 -12.11 28.94 9.59 22.33 41.34 6.93 43.48 25.59 56.03 24.24 49.99 18.61 29.05 29.16 28.57 NA NA NA NA NA NA NA NA

Operating Expenses 48.09 45.58 64.62 59.19 74.26 88.85 75.41 87.70 79.76 82.63 78.87 87.74 89.34 119.89 126.30 109.62 122.66 117.38 142.24 81.01 84.45 70.43 75.95 65.46 50.66

Research And Development Expense 20.20 19.69 31.90 27.35 26.03 43.83 29.56 40.47 37.21 40.61 37.58 46.86 52.82 81.23 80.41 74.51 85.69 82.35 87.05 70.63 71.92 61.40 68.38 58.71 43.75

Selling General And Administrative Expense 27.04 25.22 30.65 30.92 32.81 44.33 44.83 46.36 41.65 41.33 40.31 40.17 35.48 37.98 44.92 34.18 36.07 34.29 55.12 10.38 12.54 9.02 NA NA NA

Operating Income Loss -9.00 -24.94 -6.35 -48.17 33.90 -58.49 -66.16 -54.89 -79.34 -64.94 -85.40 -58.09 -173.82 -59.12 -94.89 -55.91 -59.52 -75.97 -90.16 -27.84 -35.66 -24.50 11.37 -24.18 -22.14

Interest Income Expense Nonoperating Net -1.64 -1.56 -1.64 -3.95 -5.04 -5.06 -5.08 -5.08 -4.96 -4.80 -2.32 -2.27 -2.31 -1.97 -0.79 0.23 0.48 0.87 1.74 1.78 1.56 1.08 0.91 0.84 0.61

Gains Losses On Extinguishment Of Debt NA NA 0.00 -0.91 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA

Allocated Share Based Compensation Expense 3.50 NA NA NA 6.90 NA NA NA NA 5.99 6.09 6.59 6.86 4.92 4.93 2.61 2.28 2.09 12.06 2.25 2.49 2.23 2.19 2.15 2.50

Profit Loss NA NA -4.41 -54.10 29.45 -63.51 NA NA NA NA NA NA NA -60.75 NA NA NA -72.42 NA NA NA NA NA NA NA

Net Income Loss -11.17 -26.22 -7.55 -51.87 29.28 -62.42 -70.68 -59.54 -83.04 -69.58 -87.00 -59.96 -175.75 -60.75 -94.48 -54.59 -58.17 -72.42 -60.05 -26.05 -34.07 -23.42 12.28 -23.13 -21.52

Comprehensive Income Net Of Tax -11.17 -26.22 -7.55 -51.87 29.28 -62.42 -70.68 -59.54 -83.04 -69.58 -86.99 -59.94 -175.76 -60.75 -94.49 -54.60 -58.11 -72.20 -59.91 -26.00 -33.98 -23.53 12.06 -23.06 -21.59

Net Income Loss Available To Common Stockholders Basic -11.17 -26.22 NA -51.87 29.28 -62.42 NA -59.54 -83.04 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA

Net Income Loss Available To Common Stockholders Diluted -11.17 -26.22 NA -51.87 29.28 -62.42 NA -59.54 -83.04 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA

2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30

Assets 253.71 276.86 351.83 435.89 521.80 535.36 525.55 602.27 611.86 628.70 644.14 676.14 745.17 787.72 771.20 795.22 823.53 890.79 996.54 403.83 413.78 442.71 364.25 338.59 336.82

Liabilities 280.52 291.21 342.49 422.04 459.50 509.24 449.09 465.12 437.23 414.81 396.52 358.18 374.91 391.36 376.44 327.66 304.17 324.41 360.61 261.29 247.86 245.62 244.92 238.71 279.82

Liabilities And Stockholders Equity 253.71 276.86 351.83 435.89 521.80 535.36 525.55 602.27 611.86 628.70 644.14 676.14 745.17 787.72 771.20 795.22 823.53 890.79 996.54 403.83 413.78 442.71 364.25 338.59 336.82

Stockholders Equity -26.81 -14.35 9.34 13.85 62.30 26.12 76.46 137.15 174.63 213.89 247.62 317.96 370.26 396.36 394.76 467.56 519.36 566.38 635.93 142.54 165.92 197.10 119.33 99.88 57.00

2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30

Assets Current 118.45 120.72 184.95 237.51 304.16 302.69 272.01 330.08 331.08 365.02 371.44 391.00 449.10 340.76 309.53 299.01 316.40 347.23 468.27 397.53 407.42 436.98 358.36 333.94 332.39

Cash And Cash Equivalents At Carrying Value 53.57 56.95 90.47 144.76 143.89 174.56 149.80 207.20 246.99 252.76 228.70 169.29 245.41 115.37 147.45 122.89 87.21 62.74 104.64 162.43 163.53 158.17 70.16 89.60 125.39

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 55.29 59.66 93.17 147.85 146.98 177.65 151.84 209.24 249.03 254.80 231.13 171.72 247.84 117.81 149.80 125.24 89.67 65.20 107.10 164.00 165.09 159.45 71.44 90.88 126.67

Accounts Receivable Net Current 19.57 17.78 39.18 23.09 81.87 64.58 50.88 49.69 35.01 35.23 26.85 24.47 39.12 104.87 38.86 29.65 28.89 48.44 16.67 0.69 0.13 35.85 34.22 NA NA

Inventory Net 20.91 20.60 21.76 40.04 36.27 39.42 38.20 33.69 37.90 44.81 61.02 88.24 104.60 111.85 116.35 115.99 122.14 115.21 114.25 NA NA NA NA NA NA

Prepaid Expense And Other Assets Current 24.40 25.38 33.54 29.62 42.13 24.12 33.14 39.50 11.18 12.21 14.88 9.04 10.04 8.66 6.63 7.75 28.61 15.55 15.72 6.69 5.16 8.10 6.35 3.95 11.17

2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30

Property Plant And Equipment Gross NA NA 14.53 NA NA NA 14.42 NA NA NA 14.36 14.04 14.09 14.04 14.04 16.42 13.89 11.91 9.98 5.50 5.20 4.97 4.68 4.23 3.63

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment NA NA 9.32 NA NA NA 7.67 NA NA NA 5.74 5.22 4.71 4.19 3.66 3.62 2.98 2.40 1.96 1.70 1.47 1.26 1.06 0.86 0.69

Amortization Of Intangible Assets 9.00 9.01 9.01 9.00 9.00 9.01 9.01 9.00 9.00 9.01 7.21 6.10 9.10 9.10 9.10 9.10 9.10 9.10 NA NA NA NA NA NA NA

Property Plant And Equipment Net 4.42 4.82 5.21 5.62 6.04 6.45 6.75 7.20 7.67 8.17 8.62 8.82 9.38 9.86 10.38 12.80 10.90 9.51 8.02 3.81 3.73 3.71 3.62 3.36 2.93

Goodwill 59.04 55.05 55.05 55.05 55.05 55.05 55.05 55.05 55.05 55.05 55.05 55.05 55.05 55.05 55.05 55.05 55.05 55.05 55.05 NA NA NA NA NA NA

Intangible Assets Net Excluding Goodwill 54.06 NA 72.08 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA

Finite Lived Intangible Assets Net NA 63.07 72.08 81.09 90.11 99.12 108.13 NA NA NA 144.17 151.38 157.48 282.11 291.21 300.31 309.41 318.51 328.15 NA NA NA NA NA NA

Other Assets Noncurrent 3.35 5.24 5.37 26.27 34.95 39.42 49.75 69.60 67.47 39.64 37.98 44.17 47.27 71.92 75.98 97.91 100.54 128.08 137.04 2.49 2.64 2.02 2.27 1.29 1.50

2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30

Liabilities Current 92.18 82.94 124.76 187.97 233.68 253.91 256.49 189.21 165.59 172.68 187.15 181.46 195.77 214.15 208.12 223.15 185.62 202.61 265.69 177.40 164.42 151.42 144.35 151.36 181.59

Long Term Debt Current 24.00 24.00 32.00 65.95 98.16 97.85 97.54 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA

Accounts Payable Current 11.78 12.58 18.02 19.71 24.94 19.47 33.59 28.81 41.98 30.54 41.31 40.40 29.41 54.38 39.22 64.36 19.32 15.23 42.80 12.68 4.79 17.88 7.00 8.71 10.21

Other Accrued Liabilities Current 4.48 5.13 7.41 8.49 9.78 17.03 11.26 11.46 9.24 11.75 8.64 10.33 9.73 10.26 9.55 8.76 12.80 16.93 12.08 5.90 4.51 3.22 2.37 2.28 2.44

Accrued Liabilities Current 56.41 46.37 71.00 87.36 91.28 109.66 104.46 144.70 111.74 123.89 130.62 123.02 142.83 124.89 129.07 126.64 125.98 137.80 150.92 94.62 81.01 54.95 52.44 21.43 28.85

Contract With Customer Liability Current NA NA 3.74 1.26 5.05 10.44 20.91 15.69 11.87 18.25 15.21 18.03 23.53 34.89 39.83 32.14 40.32 49.58 56.98 70.10 78.61 NA 81.67 NA NA

2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30

Long Term Debt NA NA 66.08 65.95 98.16 NA 97.54 NA NA NA 96.38 76.61 76.34 76.07 75.81 NA NA NA NA NA NA NA NA NA NA

Long Term Debt Noncurrent 18.49 26.30 34.08 NA NA NA NA 97.23 96.92 96.61 96.38 76.61 76.34 76.07 75.81 NA NA NA NA NA NA NA NA NA NA

Other Liabilities Noncurrent 17.14 12.64 12.16 74.31 66.89 77.74 82.53 77.39 85.36 53.62 60.61 40.97 41.51 30.39 30.22 30.06 29.90 29.74 29.57 0.04 0.07 0.02 0.02 0.02 0.02

Operating Lease Liability Noncurrent 11.48 27.42 28.96 30.68 31.73 32.58 33.70 20.26 21.73 23.18 24.62 23.49 24.86 26.21 27.53 NA NA NA NA NA NA NA NA NA NA

2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30

Stockholders Equity -26.81 -14.35 9.34 13.85 62.30 26.12 76.46 137.15 174.63 213.89 247.62 317.96 370.26 396.36 394.76 467.56 519.36 566.38 635.93 142.54 165.92 197.10 119.33 99.88 57.00

Common Stock Value 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Additional Paid In Capital Common Stock 1568.26 1564.77 1562.25 1559.21 1555.79 1548.88 1536.80 1526.82 1504.75 1460.97 1425.12 1408.47 1400.82 1251.16 1188.81 1167.13 1164.32 1153.23 1150.58 597.29 594.68 591.87 493.82 486.39 420.45

Retained Earnings Accumulated Deficit -1595.08 -1579.13 -1552.91 -1545.36 -1493.50 -1522.77 -1460.35 -1389.67 -1330.13 -1247.09 -1177.51 -1090.51 -1030.55 -854.80 -794.05 -699.57 -644.99 -586.82 -514.39 -454.34 -428.29 -394.23 -374.05 -386.33 -363.20

Accumulated Other Comprehensive Income Loss Net Of Tax 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 -0.01 NA 0.00 0.01 0.02 -0.04 -0.26 -0.41 -0.46 -0.55 -0.44 -0.18 -0.25

Stock Issued During Period Value New Issues NA NA NA NA NA 7.18 NA 16.09 37.27 29.50 NA NA 142.38 56.58 NA NA 9.04 NA NA 0.04 NA 95.42 NA NA NA

Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 3.49 2.49 NA 3.38 6.84 4.54 NA 5.59 6.51 5.99 NA 6.59 6.86 4.92 NA 2.61 2.28 2.09 12.06 2.25 2.49 2.23 NA NA NA

2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30

Net Cash Provided By Used In Operating Activities 3.63 -17.54 -54.68 33.80 -30.66 -21.62 -62.81 -56.27 -63.14 -70.75 -30.78 -27.24 37.22 -89.59 -92.14 10.99 -38.37 -137.93 -73.70 -12.46 9.00 -20.33 -16.38 -54.62 NA

Net Cash Provided By Used In Investing Activities NA NA 0.00 0.00 0.00 -0.11 0.00 0.00 20.00 19.94 59.68 -49.94 -49.99 0.24 22.28 24.39 54.03 110.47 16.72 11.01 -3.57 12.43 -8.31 -44.96 NA

Net Cash Provided By Used In Financing Activities -8.00 -15.97 -0.00 -32.94 -0.01 47.55 5.40 16.48 37.37 74.48 30.51 1.05 142.81 57.35 94.42 0.20 8.80 -14.45 0.09 0.35 0.21 95.91 5.24 63.78 NA

2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30

Net Cash Provided By Used In Operating Activities 3.63 -17.54 -54.68 33.80 -30.66 -21.62 -62.81 -56.27 -63.14 -70.75 -30.78 -27.24 37.22 -89.59 -92.14 10.99 -38.37 -137.93 -73.70 -12.46 9.00 -20.33 -16.38 -54.62 NA

Net Income Loss -11.17 -26.22 -7.55 -51.87 29.28 -62.42 -70.68 -59.54 -83.04 -69.58 -87.00 -59.96 -175.75 -60.75 -94.48 -54.59 -58.17 -72.42 -60.05 -26.05 -34.07 -23.42 12.28 -23.13 -21.52

Profit Loss NA NA -4.41 -54.10 29.45 -63.51 NA NA NA NA NA NA NA -60.75 NA NA NA -72.42 NA NA NA NA NA NA NA

Increase Decrease In Accounts Receivable 0.69 -21.40 16.09 -58.77 17.29 13.71 1.19 14.69 -0.23 8.38 2.39 -14.65 -65.76 66.01 9.21 0.77 -19.55 31.77 0.14 0.56 -35.72 1.64 33.94 0.28 0.00

Increase Decrease In Inventories -3.48 -7.35 -18.39 -0.25 -6.41 5.25 -9.44 -0.43 16.52 19.19 0.25 -12.10 -2.48 8.16 0.58 11.38 1.12 16.06 NA NA NA NA NA NA NA

Increase Decrease In Accounts Payable -3.04 -9.01 18.92 -8.61 -1.45 -7.36 3.20 -13.81 3.79 -4.91 0.65 8.01 -25.45 20.47 -25.07 46.07 1.12 -20.75 8.03 7.89 -13.09 10.88 -1.71 -1.51 -4.87

Share Based Compensation 3.49 2.49 3.04 3.35 6.92 4.54 4.64 5.59 6.51 5.99 6.09 6.59 6.86 4.92 4.93 2.61 2.28 2.09 12.06 2.25 2.49 2.23 2.19 2.15 2.51

2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30

Net Cash Provided By Used In Investing Activities NA NA 0.00 0.00 0.00 -0.11 0.00 0.00 20.00 19.94 59.68 -49.94 -49.99 0.24 22.28 24.39 54.03 110.47 16.72 11.01 -3.57 12.43 -8.31 -44.96 NA

Payments To Acquire Property Plant And Equipment NA NA 0.00 0.00 0.00 0.11 0.00 0.00 0.00 0.06 NA NA NA NA 0.22 2.53 1.98 1.93 0.83 0.31 0.17 0.30 0.45 0.60 0.15

2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30

Net Cash Provided By Used In Financing Activities -8.00 -15.97 -0.00 -32.94 -0.01 47.55 5.40 16.48 37.37 74.48 30.51 1.05 142.81 57.35 94.42 0.20 8.80 -14.45 0.09 0.35 0.21 95.91 5.24 63.78 NA

2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30

Revenue From Contract With Customer Excluding Assessed Tax 56.38 40.13 55.18 48.96 126.76 61.70 59.60 48.76 52.91 52.30 56.70 59.99 90.14 88.48 69.56 91.98 100.80 72.67 59.85 53.17 48.79 45.93 90.56 41.28 28.52

Mitsubishi Tanabe Pharma Corporation 0.60 3.40 -0.60 0.40 0.40 1.60 -0.10 0.40 0.10 0.40 NA 0.40 NA NA NA NA NA NA NA NA 0.20 NA NA NA NA

Japan Tobacco Incorporation And Torii Pharmaceutical Company Limited, License Collaboration And Other Revenue 1.39 1.14 1.42 1.24 1.49 1.15 1.72 1.44 1.49 1.16 1.63 1.18 1.74 1.13 1.62 1.55 1.49 1.23 NA NA NA NA NA NA NA

M E D I C E Arzneimittel Putter Gmb H Co K G, License Collaboration And Other Revenue 10.00 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA

Mitsubishi Tanabe Pharma Corporation, License Collaboration And Other Revenue 0.52 4.16 4.08 5.49 0.43 7.96 5.27 2.56 4.59 0.02 0.03 0.37 15.00 0.00 0.00 0.00 10.00 0.00 0.00 0.00 0.19 9.09 NA NA NA

Mitsubishi Tanabe Pharma Corporation, License Collaboration And Other Revenue Royalties 0.50 0.40 NA 0.40 0.40 0.30 NA 0.30 0.10 0.00 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA

Mitsubishi Tanabe Pharma Corporation And Otsuka Pharmaceutical Company Limited, License Collaboration And Other Revenue 2.74 4.16 4.08 5.49 81.57 19.10 15.79 10.56 18.46 20.66 18.76 23.87 53.72 57.95 38.82 59.94 69.99 48.18 52.93 53.14 48.73 45.66 NA NA NA

Otsuka Pharmaceutical Company Limited, License Collaboration And Other Revenue, Development And Commercialize International Collaboration And License Agreement NA NA 0.00 0.00 0.00 5.50 2.92 1.86 4.70 6.97 6.01 7.24 12.83 19.37 10.97 20.22 22.47 21.96 24.14 24.11 22.09 16.97 NA NA NA

Otsuka Pharmaceutical Company Limited, License Collaboration And Other Revenue, Development And Commercialize United States Collaboration And License Agreement 2.23 NA 0.00 0.00 81.14 5.64 7.60 6.14 9.17 13.67 12.72 16.26 25.89 38.58 27.85 39.72 37.52 26.22 28.78 29.03 26.46 19.60 NA NA NA

Otsuka Pharmaceutical Company Limited, License Collaboration And Other Revenue, Packaging Validation Transfer Agreement 2.20 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA

Japan Tobacco Incorporation And Torii Pharmaceutical Company Limited, Sublicense Agreement 1.40 1.10 1.40 1.20 1.50 1.10 1.70 1.40 1.50 1.20 1.70 1.20 1.70 1.10 1.60 1.50 1.50 1.20 0.10 NA NA NA NA NA NA

License Collaboration And Other Revenue 14.13 5.30 5.50 6.72 83.06 20.25 17.51 12.00 19.95 21.90 22.09 25.60 59.45 59.27 40.64 61.97 71.71 49.55 53.03 53.17 48.79 45.93 NA NA NA

Product 42.24 34.83 49.68 42.24 43.70 41.45 42.10 36.75 32.96 30.41 34.60 34.39 30.70 29.21 28.91 30.00 29.09 23.11 6.82 NA NA NA NA NA NA

Product, NA -0.12 0.60 -0.25 -0.39 -0.08 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA

Product, NA 34.83 49.68 42.24 43.70 41.45 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA

Plots across concepts

IncomeStatement

Expenses

Balance Sheet

Assets

Current Assets

NonCurrent Assets

PropertyPlantAndEquipmentNet

Liabilities

Current Liabilities

Noncurrent Liabilities

Stockholders Equity

CashFlow

NetCashProvidedByUsedInOperatingActivities

NetCashProvidedByUsedInInvestingActivities

OperatingLeaseLiability

LesseeOperatingLeaseLiabilityPaymentsDue

FiniteLivedIntangibleAssets

InventoryNet

Line plots across dimensions of each concept

us-gaap:EarningsPerShareBasic
us-gaap:Restatement
(None,)

us-gaap:EarningsPerShareDiluted
us-gaap:Restatement
(None,)

TTM Greenblatt ROC
_
(None,)

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService
(None,)

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:CounterpartyName, us-gaap:ProductOrService
(None, 'akba:LicenseCollaborationAndOtherRevenue')

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:CounterpartyName, us-gaap:ProductOrService
('akba:MitsubishiTanabePharmaCorporation', None)

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement
('akba:OtsukaPharmaceuticalCompanyLimited', 'akba:LicenseCollaborationAndOtherRevenue', None)

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:Restatement
('us-gaap:Product', None)

us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
us-gaap:Restatement
(None,)

us-gaap:ResearchAndDevelopmentExpense
us-gaap:Restatement
(None,)

us-gaap:SellingGeneralAndAdministrativeExpense
us-gaap:Restatement
(None,)

us-gaap:OperatingIncomeLoss
us-gaap:Restatement
(None,)

us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:IncomeStatementLocation
(None,)

us-gaap:ProfitLoss
us-gaap:Restatement
(None,)

us-gaap:NetIncomeLoss
us-gaap:Restatement
(None,)

us-gaap:ComprehensiveIncomeNetOfTax
us-gaap:Restatement
(None,)

us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
us-gaap:Restatement
(None,)

us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
us-gaap:Restatement
(None,)

us-gaap:Assets
us-gaap:Restatement
(None,)

us-gaap:Liabilities
us-gaap:Restatement
(None,)

us-gaap:LiabilitiesAndStockholdersEquity
us-gaap:Restatement
(None,)

us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents
(None,)

us-gaap:StockholdersEquity
us-gaap:Restatement
(None,)

us-gaap:StockholdersEquity
us-gaap:Restatement, us-gaap:StatementEquityComponents
(None, 'us-gaap:RetainedEarnings')

us-gaap:AssetsCurrent
us-gaap:Restatement
(None,)

us-gaap:AccountsReceivableNetCurrent
us-gaap:Restatement
(None,)

us-gaap:InventoryNet
us-gaap:Restatement
(None,)

us-gaap:PrepaidExpenseAndOtherAssetsCurrent
us-gaap:Restatement
(None,)

us-gaap:PropertyPlantAndEquipmentGross
us-gaap:PropertyPlantAndEquipmentByType
(None,)

us-gaap:OtherAssetsNoncurrent
us-gaap:Restatement
(None,)

us-gaap:LiabilitiesCurrent
us-gaap:Restatement
(None,)

us-gaap:AccruedLiabilitiesCurrent
us-gaap:Restatement
(None,)

us-gaap:ContractWithCustomerLiabilityCurrent
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
('akba:OtsukaPharmaceuticalCompanyLimited', None)

us-gaap:OtherLiabilitiesNoncurrent
us-gaap:Restatement
(None,)